Third hospital in the Philippines receives special permit to use Ivermectin to treat Covid-19

MANILA, Philippines — The Philippine Food and Drug Administration granted Wednesday yet another private hospital a compassionate special permit (CSP) to use anti-parasitic drug ivermectin as a treatment for COVID-19.

FDA Director General Eric Domingo revealed this during a congressional inquiry on Thursday.

This is the third hospital to get a CSP for ivermectin following two private hospitals which received the same authorization. Another hospital has a pending CSP application for ivermectin, Domingo said.

Domingo said he could not disclose what hospitals were granted the special permit supposedly to protect the privacy of patients.

A CSP allows doctors or hospitals to use unregistered medical products for limited off-label use. A specialized institution or speciality society will be the only ones to file a request for CSPs.

Ivermectin is only registered for human use as a topical cream in the Philippines, but oral formulations of the drug can be obtained from hospitals with CSPs or from registered pharmacies compounding it upon the prescription of a doctor.

Any prescription of it for the prevention or treatment of COVID-19, however, is considered off-label use and is not endorsed by the Department of Health or the FDA.

The World Health Organization also does not recommend using ivermectin on COVID-19 patients except in a clinical trial.

It also said the effects of ivermectin on mortality, mechanical ventilation, hospital admission, duration of hospitalization and viral clearance “remain uncertain because of very low certainty of evidence addressing each of these outcomes.”

A review by several medical groups in the country of six trials of ivermectin showed that it did not significantly reduce the risk of death among patients with COVID-19 and did not significantly reduce time in the hospital.

Ivermectin is also not associated with a definite benefit in terms of other clinically important outcomes. There is also no significant difference in the rate of hospital discharge between patients who took the anti-parasitic drug and those who did not.

That said, dozens of clinical trials on the use of Ivermectin for the treatment of COVID-19 are still ongoing, which means the final verdict for ivermectin has yet to be handed down.

98% of the 52 studies to date report positive effects (25 statistically significant in isolation). Random effects meta-analysis for early treatment and pooled effects shows an 81% reduction, RR 0.19 [0.09-0.38], and prophylactic use shows 85% improvement, RR 0.15 [0.09-0.25]. Mortality results show 76% lower mortality, RR 0.24 [0.14-0.42] for all treatment delays, and 84% lower, RR 0.16 [0.04-0.63] for early treatment.

•96% of the 27 Randomized Controlled Trials (RCTs) report positive effects, with an estimated 65% improvement, RR 0.35 [0.24-0.52].

•The probability that an ineffective treatment generated results as positive as the 52 studies to date is estimated to be 1 in 85 trillion (p = 0.000000000000012).

https://ivmmeta.com/

Ivermectin is good therapy for Covid 19 but it has to be administered during the first 5 days of infection. Once the lungs fill with mucus, it has a very limited efficacy.

If we had a public health edifice that was worth anything, front line health care workers and public-facing store employees would be on Covid prophylaxis, and could have been for months. The Federal public health agencies (FDA/NIH/CDC) have seemingly completely ignored cheap effective re-purposed therapeutics that could have significantly reduced deaths and transmission.

Ivermectin is effective for COVID-19: meta analysis of 35 studies https://ivmmeta.com/

Front Line COVID-19 Critical Care Alliance https://covid19criticalcare.com/

Key protocols from this group use Ivermectin.

COVID Care for Clinicians

https://www.evms.edu/covid-19/covid_care_for_clinicians/

Ditto this group.

India has been using HCQ and Ivermectin for many months as therapeutics and for prophylaxis. Their curves are quite impressive, scroll down to see them here.

https://www.worldometers.info/coronavirus/country/india/

Anyone able to interpret a basic graph will be impressed. Why is this not being talked about in Western media?

Also from India:

Ziverdo Kit Contains Zinc Acetate 50 mg, Doxycycline 100 mg & Ivermectin 12 mg Dispersible Tablets. It is currently indicated in the first line treatment for COVID-19 positive patients. Quadruple Therapy with Ivermectin is effective in treating COVID-19

https://www.rxindia.com/medicines/medicines-by-therapeutic-class/covid-19/ziverdo-kit/

That’s a link to an Indian online pharmacy selling that Covid treatment kit for under $2, just add vitamin D3.

The Mystery Behind India’s Success in Flattening the Curve

https://covexit.com/the-mystery-behind-india-success-in-flattening-the-curve/ Hint: There are a several hundred million HCQ and Ivermectin tablets as a key component of early therapeutic regimens.

Also, the meta-study link has links to a number of other studies. Here’s the one for HCQ.

HCQ is effective for COVID-19 when used early: real-time meta analysis of 197 studies

https://hcqmeta.com/

The War on ‘Misinformation’ Claims Two Victims. Truth. And the Right to Treatment.

https://trialsitenews.com/the-war-on-misinformation-claims-two-victims-truth-and-the-right-to-treatment/

I continue to think the media, Big Tech and FedGov’s handling of these therapeutics criminal.

Watch this video, Dr, Pierre Cory Demonstrates that Ivermectin is a successful treatment:

https://www.youtube.com/watch?v=1VQcKdP7BQc